Can a Pre-Dose stop a dangerous immune reaction?
Disease control
Recruiting now
This early-phase trial tests whether giving siltuximab before epcoritamab can prevent cytokine release syndrome (CRS), a common and sometimes severe side effect. About 20 adults with non-Hodgkin lymphoma will receive siltuximab one hour before their first epcoritamab dose. Resear…
Phase: PHASE1 • Sponsor: Taylor Brooks • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC